Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation
Pharmaceutics · 29.04.2026 · 18 (5) · 548
DOI: 10.3390/pharmaceutics18050548 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.04.2026. Verfasst von Xiaohong Jing und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Metal–organic frameworks (MOFs) are porous hybrid nanomaterials assembled from metal ions or clusters and organic ligands. Owing to their tunable structures, versatile compositions, and exceptional payload capacities, MOF-based systems have attracted increasing interest in drug delivery and theranostics. Yet, despite rapid progress in efficacy-focused studies, translational evaluation remains limited by incomplete evidence on safety, in vivo fate (pharmacokinetics), and degradation. This review examines MOF nanomedicines through a three-element evidence-chain framework and a four-level material evaluation and substantiation (MES) grading system to relate commonly reported endpoints to development-relevant questions. Major degradation patterns across representative MOF families are summarized, and the influence of surface engineering on safety, in vivo fate, and degradation is discussed. Representative studies are re-examined to illustrate how evidence gaps in these dimensions may affect translational interpretation. Key priorities for the field include dose standardization, quantitative in vivo evaluation, harmonized degradation assays, long-term and repeat-dose studies, and more consistent formulation reporting. By integrating these issues into a unified evidence-chain framework, this review aims to support a more comparable, interpretable, and development-relevant evaluation of MOF nanomedicine research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
ORCID-Profile: Xiaohong Jing, Xingbin Yin
Förderung
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Jing, X., Ma, Y., Liu, Y., & Yin, X. (2026). Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation. Pharmaceutics, 18(5), 548. https://doi.org/10.3390/pharmaceutics18050548
Vancouver
Jing X, Ma Y, Liu Y, Yin X. Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation. Pharmaceutics. 2026;18(5):548. doi:10.3390/pharmaceutics18050548
BibTeX
@article{Jing2026,
author = {Jing, Xiaohong and Ma, Yuqian and Liu, Yi and Yin, Xingbin},
title = {Safety, In Vivo Fate, and Degradation of MOF Nanomedicines: Toward Translational Evaluation},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {548},
doi = {10.3390/pharmaceutics18050548}
}
EUVIMED